X4 Pharmaceuticals, Inc (XFOR) Cash Flow Statement
X4 Pharmaceuticals, Inc (XFOR) generated -$83.7M of operating cash flow over the twelve months to 2026-06-30, spent $0 on capital expenditure and had free cash flow of -$83.7M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
XFORX4 Pharmaceuticals, IncFollow XFOR — free
—
Price chart with a free account
- Market cap
- 321.2M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
| Line | FY2020 Dec 20 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Operating cash flow | -58.8 | -130.9 | -85.6 | -83.7 | |
| Capital expenditure | 1.4 | 0.3 | 0.0 | -0.0 | |
| Free cash flow | -60.2 | -131.2 | -85.6 | -83.7 | |
| Dividends paid | 0.0 | 0.0 | 0.0 | — | |
| Stock-based compensation | 5.4 | 8.2 | 4.3 | — |
USD millions · SEC XBRL
X4 Pharmaceuticals, Inc — questions
- What is X4 Pharmaceuticals, Inc's operating cash flow?
- -$83.7M over the twelve months to 2026-06-30.
- How much does X4 Pharmaceuticals, Inc spend on capital expenditure?
- $0 over the twelve months to 2026-06-30.
- What is X4 Pharmaceuticals, Inc's free cash flow?
- -$83.7M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from X4 Pharmaceuticals, Inc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.